Washington, D.C., January 12, 2021 – Today, the Coalition for Affordable Prescription Drugs released the following statement regarding the legal challenge filed by the Pharmaceutical Care Management Association (PCMA) against the Trump Administration’s Rebate Rule:
“Since the Trump Administration first announced the Rebate Rule in 2018, CAPD has opposed this misguided policy that according to HHS’ own analysis and the AARP, threatens to raise Medicare Part D premiums for seniors by up to 25% and increase Medicare spending by nearly $200 billion – all while handing Big Pharma a windfall. Despite HHS Secretary Alex Azar acknowledging the previously withdrawn Rule could increase premiums, it was rushed through in the waning days of the Trump Administration, circumventing government actuaries and the proper rulemaking process. The Rebate Rule threatens to destabilize the Medicare Part D program for seniors, just when they need it most.
“CAPD supports PCMA’s legal challenge to the Rebate Rule filed today, joining a widespread group of stakeholders in calling on the incoming Biden Administration and Congress to protect seniors by overturning this rule and enacting reforms that will encourage pharmaceutical companies to lower the prices they set for drugs.”